AMO Pharma Ltd. logo

AMO Pharma Ltd.

AMO Pharma is a privately held biopharmaceutical company developing new treatments for serious and debilitating diseases including rare genetic disorders.

AMO Pharmas lead product candidate, AMO-02, in the treatment of a severe form of myotonic dystrophy (DM) known as DM1 or Steinerts disease. Myotonic dystrophy is a genetic disorder that causes skeletal and muscle weakness and dysfunction, cognitive deficits, as well as symptoms affecting other organs in the body.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.amo-pharma.com
Founded2015
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
Kemp House, 152-160 City Road, London, EC1V 2NX
London
United Kingdom
Email
Contact Number
+44 1483 319070

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/amo-pharma-limited” connections=”true” suffix=””]

In Sep. 2015, AMO Pharma raised $25 Mn in (Series A financing from Woodford Investment Management. Funding will support Company efforts to advance two clinical-stage pipeline assets targeting rare muscular and CNS disorders.